Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Quick facts
Marketed products
- Cabotegravir LA + Rilpivirine LA · Infectious Disease / Virology
Cabotegravir and rilpivirine are long-acting antiretroviral agents that inhibit HIV integrase and reverse transcriptase, respectively, preventing viral replication.
Phase 3 pipeline
- Hipec with Cisplatin · Oncology
HIPEC (hyperthermic intraperitoneal chemotherapy) with cisplatin delivers heated chemotherapy directly into the peritoneal cavity to treat intra-abdominal malignancies.
Phase 2 pipeline
- Alprostadil 20 micrograms · Cardiovascular
Alprostadil is a prostaglandin E1 analog that vasodilates blood vessels and inhibits platelet aggregation.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia portfolio CI brief
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia pipeline updates RSS
Frequently asked questions about Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
What are Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia's marketed drugs?
Top marketed products include Cabotegravir LA + Rilpivirine LA.
What is Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia's pipeline?
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia has 1 drugs in Phase 3, 1 in Phase 2, 1 in Phase 1. Late-stage candidates include Hipec with Cisplatin.
Related
- Cabotegravir LA + Rilpivirine LA · Infectious Disease / Virology
- Sector hub: All tracked pharma companies